Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-04-03
2007-04-03
Haddad, Maher M. (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C536S023500, C435S325000, C435S252300, C435S320100
Reexamination Certificate
active
10785220
ABSTRACT:
The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245.
REFERENCES:
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 5650295 (1997-07-01), Li et al.
patent: 6022708 (2000-02-01), de Sauvage et al.
patent: 6358707 (2002-03-01), Gupta et al.
patent: 6410708 (2002-06-01), Askenazi et al.
patent: 2002/0172994 (1997-03-01), Ruben et al.
patent: 2003/0017563 (1997-03-01), Baker et al.
patent: 2003/0032155 (1997-03-01), Baker et al.
patent: 2003/0036180 (1997-03-01), Baker et al.
patent: 2003/0321550 (1997-03-01), Baker et al.
patent: 2002/0182206 (1997-11-01), Ashkenazi et al.
patent: 2002/0065394 (1998-03-01), Jacobs et al.
patent: 2003/0004311 (1998-06-01), Baker et al.
patent: 2002/0177165 (1998-07-01), Ashkenazi et al.
patent: 2003/0032057 (1998-07-01), Ashkenazi et al.
patent: 2003/0032062 (1998-07-01), Ashkenazi et al.
patent: 2002/0077287 (1998-09-01), Ruben et al.
patent: 2002/0132240 (1998-09-01), Ashkenazi et al.
patent: 2002/0146709 (1998-09-01), Ashkenazi et al.
patent: 2002/0160374 (1998-09-01), Ashkenazi et al.
patent: 2002/0192659 (1998-09-01), Ashkenazi et al.
patent: 2002/0197671 (1998-09-01), Ashkenazi et al.
patent: 2003/0003530 (1998-09-01), Ashkenazi et al.
patent: 2003/0017463 (1998-09-01), Ashkenazi et al.
patent: 2003/0023054 (1998-09-01), Ashkenazi et al.
patent: 2003/0027143 (1998-09-01), Ashkenazi et al.
patent: 2003/0032063 (1998-09-01), Ashkenazi et al.
patent: 2002/0169284 (1998-10-01), Ashkenazi et al.
patent: 2002/0177553 (1998-10-01), Ashkenazi et al.
patent: 2002/0192706 (1998-10-01), Ashkenazi et al.
patent: 2003/0004102 (1998-10-01), Ashkenazi et al.
patent: 2002/0090672 (2000-01-01), Rosen et al.
patent: 2001/0077137 (2000-04-01), Rosen et al.
patent: 2002/0076756 (2001-02-01), Ruben et al.
patent: 2002/0095010 (2001-03-01), Rosen et al.
patent: 199141 (1986-10-01), None
patent: 317050 (1989-05-01), None
patent: WO 90/05537 (1990-05-01), None
patent: WO 96/34943 (1996-11-01), None
patent: WO 98/24897 (1998-06-01), None
patent: WO 98/40483 (1998-09-01), None
patent: WO 98/42739 (1998-10-01), None
patent: WO 99/02561 (1999-01-01), None
patent: WO 00/29583 (2000-05-01), None
Sobocka et al Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation.Blood. Apr. 15, 2000;95(8):2600-9.
Naik et al .Mechanisms of platelet activation by a stimulatory antibody: cross-linking of a novel platelet receptor for monoclonal antibody F11 with the Fc gamma RII receptor. Biochem J. Aug. 15, 1995;310 ( Pt 1):155-62.
Alberst et al. Molecular Biolgoy of the cell. 2nded. pp. 163-196 &259-271, 1989.
Attwood TK. Genomics. The Babel of bioinformatics. Science. 290(5491):471-473, 2000.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. 18(1):34-9, 2000.
Ozaki et al, “Cutting Edge: Combined Treatment of the TNF-alpha and IFN-gamma causes Redistribution of Junctional Adhesion Molecule in Human Endothelial Cells”, J. Immunol., vol. 163, No. 2, Jul. 15, 1999.
Alderson et al., “Molecular and Biological Characterization of Human 4—1BB and Its Ligand.”European Journal of Immunology.24(9):2219-2227 (Sep. 1994).
Altschul and Gish, “Local Alignment Statistics”Methods in Enzymology266:460-480 (1996).
Auffray et al., “H. sapienspartial cDNA sequence; clone c-0xd10. partial cDNA sequence; transcribed sequence fragment” (Database EMBL—EMEST16 Accession No. F02373) (Jan. 28, 1995).
Chambers and Allison., “Co-Stimulation in T Cell Responses.”Current Opinion in Immunology.9(3) :396-404 (Jun. 1997).
De Smet et al., “The Activation of Human Gene MAGE-1 in Tumor Cells is Correlated with Genome-Wide Demethylation.”Proc. Natl. Acad. Sci. USA93(14) :7149-7153 (Jul. 9, 1996).
Finn and Lotze., “Introduction: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer.”Journal of Immunotherapy.21(2) :114-118 (Mar. 1998).
GBTRANS Database, Accession No. AF172398 (blast results) (Direct Submission Feb. 26, 2001).
GBTRANS Database, Accession No. AF191495 (blast results) (Direct Submission Oct. 1, 1999).
GBTRANS Database, Accession No. AJ132502, “HSA132502—1 Z39Ig protein—Homo sapiens” (blast results) (Direct Submission Jan. 25, 1999).
GBTRANS Database, Accession No. AL034397, “HS159A1—1 (novel protein)—Homo sapiens” (blast results) (Direct Submission Dec. 4, 1998).
GBTRANS Database, Accession No. AL136649, “HSM801619—1 hypothetical protein” (blast results) (Direct Submission Jan. 18, 2000).
GBTRANS Database, Accession No. AY016009 (blast results) (Direct Submission Dec. 4, 2000).
Heath et al., “The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily”Proc. Natl. Acad. Sci. USA94(2) :469-474 (Jan. 21, 1997).
Hellstrom and Hellstrom., “T Cell Immunity to Tumor Antigens.”Critical Reviews in Immunology.18(1-2) :1-6 (1998).
Hiller et al., “zb18h08.rl Soares fetal lung NbHL19WHomo sapienscDNA clone 302463 5′” (Database EMBL—EMEST13 Accession No. W17367) (May 4, 1996).
Hiller et al., “zd74g06.rl Soares fetal heart NbHH19WHomo sapienscDNA clone 346426 5′” (Database EMBL—EMEST14 Accession No. W79882) (Jun. 27, 1996).
“Isolation of Mouse Mononuclear Cells”Current Protocols in Immunology,Coligan et al. eds., John Wiley & Sons, Inc. vol. 1:unit 3.1.2 (1993).
Jenkins, M., “The Ups and Downs of T Cell Costimulation.”Immunity.1(6):443-446 (Sep. 1994).
June et al., “The B7 and CD28 Receptor Families.”Immunology Today.15(7):321-331 (Jul. 1994).
Kwon et al., “Manipulation of T Cell Costimulatory and Inhibitory Signals for Immunotherapy of Prostate Cancer.”Proc. Natl. Acad. Sci. USA94(15):8099-8103 (Jul. 22, 1997).
Linsley and Ledbetter., “The Role of the CD28 Receptor During T Cell Responses to Antigen.”Annu. Rev. Immunol.11:191-212 (1993).
Lynch et al., “Flt3 Ligand Induces Tumor Regression and Antitumor Immune Responses In Vivo.”Nature Medicine.3(6):625-631 (Jun. 1997).
Martin-Padura et al., “Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration”Journal of Cell Biology142(1):117-127 (Jul. 13, 1998).
Melero et al., “Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors.”Nature Medicine.3(6):682-685 (Jun. 1997).
Monks et al., “Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines”J. Natl. Cancer Institute83(11):757-766 (Jun. 5, 1991).
REFSEQ Database, Accession No. NM—016946 (blast results) (1999).
REFSEQ Database, Accession No. NM—021219 (blast results) (2000).
Schwartz, R., “Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy.”Cell.71(7):1065-1068 (Dec. 24, 1992).
Skehan et al., “New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening”J. Natl. Cancer Institute82(13):1107-1112 (Jul. 4, 1990).
Swissprot (SPROT) Database, Accession No. P57087, “VEJA—Human Vascular endothelial junction-associated molecule precursor—Homo sapiens” (blast results) (2000).
Swissprot (SPROT) Database, Accession No. Q9Y624, “JAM1—HUMAN Junctional adhesion molecule precursor—Homo sapiens” (blast results) (1999).
Wal
Ashkenazi Avi
Fong Sherman
Goddard Audrey
Gurney Austin L.
Napier Mary A.
Barnes Elizabeth M.
Dreger, Esq. Ginger R.
Genentech Inc.
Haddad Maher M.
Kresnak Mark T.
LandOfFree
Compounds, compositions and methods for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, compositions and methods for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, compositions and methods for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3789094